

Alloimmunity & Trauma

Team Pham

19 November, 2018

Contents

Tables	1
Table 4: Outcomes analysis	1
Supplemental Figure 1: Antibody Frequency by Gender	1
Supplemental Figure 2: Antibody Frequency by Race	1

Tables

Table 4: Outcomes analysis

Supplemental Figure 1: Antibody Frequency by Gender

Supplemental Figure 2: Antibody Frequency by Race

Table 1: Demographics

	Anti- (n = 4117)	Anti+ (n = 66)	p^a
age (mean (sd))	47.33 (19.16)	48.32 (20.74)	0.677
gender (%)			0.396
F	1183 (28.7)	24 (36.4)	
M	2933 (71.2)	42 (63.6)	
U	1 (0.0)	0 (0.0)	
race = Other (%)	2897 (70.4)	47 (71.2)	0.989
death = 1 (%)	4117 (100.0)	66 (100.0)	NA
los (median [IQR])	11.66 [5.99, 22.58]	38.16 [24.50, 60.10]	<0.001
RBCtrans (median [IQR])	2.00 [0.00, 6.00]	16.50 [9.00, 29.00]	<0.001
plasmatrans (median [IQR])	0.00 [0.00, 2.00]	5.50 [1.00, 21.00]	<0.001
cryop (median [IQR])	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	NaN
pp (median [IQR])	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	NaN
ntest (median [IQR])	2.00 [1.00, 3.00]	7.00 [4.25, 11.75]	<0.001

Table 2: Antibody Specificity

Antibody	Pre Admission	Post Admission
c	1	0
C	4	2
Cw	1	0
D	4	7
e	1	0
E	16	15
Fya	1	1
Jka	1	6
Jkb	2	0
K	9	0
Lea	1	4
Leb	1	1
M	9	3
NSE	12	28
S	1	1
V	1	0
A1	0	1

Table 3: Transfusion and Antibody Development

Number of RBC transfusion	Anti-	Anti+	% Developed Antibody During Encounter
0	1568	1	0.0637349
1-5	1349	8	0.5895357
6-10	619	12	1.9017433
11-20	368	19	4.9095607
>20	213	26	10.8786611